Safety Study of Adenovirus Hepatocyte Growth Factor to Treat Ischemic Heart Disease

Inclusion Criteria: * person with ischemic heart disease; * Male or female of 20 to 70 years old; * No blood perfusion detected in some area of heart using Single-Photon Emission Computed Tomography(SPECT) or Magnetic Resonance Imaging(MRI) * two or more than two coronary arteries lesions were detected using coronary artery angiography and at least one coronary artery are un-suitable for percutaneous coronary intervention (PCI) or Coronary artery bypass grafting (CABG)；Or patients refuse to perform PCI or CABG * LVEF is ≤45%; * Patients must sign approved informed consent. Exclusion Criteria: * Acute myocardial infarction occured within one week * CABG performed within 6 months or PCI performed within 3 months * Patients with systemic active infection * Blood alanine aminotransferase (ALT)\>135mmol/L or blood crea(Cr)\>200umol/L or patients with chronic obstructive pulmonary disease (COPD) * patients with obvious bleeding tendency and blood disease * patients with malignant tumor or end-stage disease * patient anticipated life expectancy is less than 12 months * patient recently attended test drugs or other device research